| |
Number
|
Age
|
Sex
| |
Disease
| |
Erosive
|
|---|
| |
of subjects
|
(years)
|
(F/total)
| |
duration (years)
|
CRP
|
disease
|
|---|
|
All patients
|
45
|
55
|
34/45
| |
10
|
15
|
27/42
|
| | |
(23–86)
|
(76%)
| |
(0.5–30)
|
(0–95)
|
(64%)
|
|
Patients with
| |
54
|
15/19
| |
8
|
10
|
12/18
|
|
high anti-CII levels
|
19
|
(31–86)
|
(79%)
| |
(0.5–30)
|
(0–95)
|
(67%)
|
|
Patients with low
|
26
|
55
|
19/26
| |
12.5
|
20
|
15/24
|
|
anti-CII levels
| |
(23–78)
|
(73%)
| |
(2.0–30)
|
(0–62)
|
(63%)
|
|
Healthy controls
|
25
|
51
|
22/25
| |
–
|
ND
|
–
|
| | |
(36–61)
|
(88%)
| | | | |
| |
Number of
|
Number of
| | |
Mean daily
| | |
| |
swollen
|
tender
|
NSAID
|
Steroid
|
prednisolone
|
MTX
|
DMARD
|
| |
joints
|
joints
|
therapy
|
therapy
|
dosage
|
therapy
|
therapy
|
|
All patients
|
2
|
4
|
26/42
|
13/42
|
2.0
|
13/42
|
30/42
|
| |
(0–17)
|
(0–17)
|
(62%)
|
(31%)
| |
(31%)
|
(71%)
|
|
Patients with
|
9
|
6
|
10/18
|
4/18
|
1.1
|
5/18
|
9/18
|
|
high anti-CII levels
|
(0–17)
|
(0–17)
|
(56%)
|
(22%)
| |
(28%)
|
(50%)
|
|
Patients with low
|
2
|
3
|
16/24
|
9/24
|
/2.7
|
8/24
|
21/24
|
|
anti-CII levels
|
(0-15)
|
(0–16)
|
(67%)
|
(38%)
| |
(33%)
|
(88%)
|
|
Healthy controls
|
–
|
–
|
–
|
–
|
–
|
–
|
–
|
- Data are given as median values and ranges for the various groups. Daily prednisolone dosages are presented as mean values in mg. Disease Modifying antirheumatic drugs (DMARDs) include sulfasalazin (0/18 high anti-CII patients treated, 6/24 low anti-CII patients treated,), cyklosporine (1/18 high anti-CII, 1/24 low anti-CII), Reumacon (a podophyllin derivative, 1/18 high anti-CII, 1/24 low anti-CII), chloroquine (0/18 high anti-CII, 2/24 low anti-CII), aurathiomalase (0/18 high anti-CII, 3/24 low anti-CII), auranofin (1/18 high anti-CII, 0/24 low anti-CII) and azatioprin (1/18 high Anti-CII, 1/24 low anti-CII). Figures for sex distribution, erosiveness and medications are given both as fraction of number positive/number Investigated, and as percentage. Data on erosive disease are based on X-ray evaluations. Patient charts were not available for three patients, one With high anti-CII levels and two with low anti-CII levels. F, female; CRP, C-reactive protein; NSAID, nonsteroidal anti-inflammatory drug; MTX, Methotrexate; ND, not done; CII, collagen type II.
